Comparing Bioventus (NYSE:BVS) and Retractable Technologies (NYSE:RVP)

Bioventus (NYSE:BVS) and Retractable Technologies (NYSE:RVP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Profitability

This table compares Bioventus and Retractable Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioventus	-7.11%	15.61%	4.01%
Retractable Technologies	-41.11%	-17.15%	-9.33%

Analyst Ratings

This is a summary of recent recommendations and price targets for Bioventus and Retractable Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0	1	3	0	2.75
Retractable Technologies	0	0	0	0	0.00

Bioventus currently has a consensus price target of $13.75, indicating a potential upside of 106.46%. Given Bioventus’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Bioventus is more favorable than Retractable Technologies.

Institutional & Insider Ownership

62.9% of Bioventus shares are held by institutional investors. Comparatively, 7.6% of Retractable Technologies shares are held by institutional investors. 33.0% of Bioventus shares are held by company insiders. Comparatively, 57.1% of Retractable Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Bioventus has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, Retractable Technologies has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.

Earnings and Valuation

This table compares Bioventus and Retractable Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$564.14 million	0.98	-$156.23 million	N/A	N/A
Retractable Technologies	$38.16 million	0.66	-$7.01 million	($0.29)	-2.88

Retractable Technologies has lower revenue, but higher earnings than Bioventus.

Summary

Bioventus beats Retractable Technologies on 9 of the 13 factors compared between the two stocks.

About Bioventus

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

About Retractable Technologies

Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.